Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
J Clin Oncol
    February 2025
  1. KAMAT AM, Frankel P
    Rethinking the Path to Bladder Cancer Staging: Can Magnetic Resonance Imaging Speed Up Time to Receipt of Therapy in Patients With Muscle-Invasive Bladder Cancer?
    J Clin Oncol. 2025 Feb 5:JCO2402482. doi: 10.1200/JCO-24-02482.
    >> Share

    January 2025
  2. BRYAN RT, Liu W, Pirrie SJ, Amir R, et al
    Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.
    J Clin Oncol. 2025 Jan 14:JCO2302398. doi: 10.1200/JCO.23.02398.
    >> Share

  3. GALSKY MD, Witjes JA, Gschwend JE, Milowsky MI, et al
    Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
    J Clin Oncol. 2025;43:15-21.
    >> Share

    December 2024
  4. GEYNISMAN DM, Abbosh PH, Ross E, Zibelman MR, et al
    Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
    J Clin Oncol. 2024 Dec 16:JCO2401214. doi: 10.1200/JCO-24-01214.
    >> Share

    October 2024
  5. MARCQ G, Kool R, Dragomir A, Kulkarni GS, et al
    Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis.
    J Clin Oncol. 2024 Oct 3:JCO2302718. doi: 10.1200/JCO.23.02718.
    >> Share

    September 2024
  6. MERCINELLI C, Moschini M, Cigliola A, Mattorre B, et al
    First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2024 Sep 6:JCO2400576. doi: 10.1200/JCO.24.00576.
    >> Share

  7. DAHL DM, Rodgers JP, Shipley WU, Michaelson MD, et al
    Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
    J Clin Oncol. 2024 Sep 3:JCO2302510. doi: 10.1200/JCO.23.02510.
    >> Share

    July 2024
  8. KLUMPER N, Tran NK, Zschabitz S, Hahn O, et al
    NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.
    J Clin Oncol. 2024;42:2446-2455.
    >> Share

    April 2024
  9. SHENG X, Wang L, He Z, Shi Y, et al
    Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
    J Clin Oncol. 2024;42:1391-1402.
    >> Share

    December 2023
  10. HE W, Zeng S, Xu C
    Controversy Surrounding Bladder-Sparing Radical Dose Radiotherapy as an Alternative to Radical Cystectomy for Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Dec 5:JCO2301920. doi: 10.1200/JCO.23.01920.
    >> Share

    November 2023
  11. CATHOMAS R, Rothschild SI, Hayoz S, Bubendorf L, et al
    Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
    J Clin Oncol. 2023;41:5131-5139.
    >> Share

    October 2023
  12. KAMAT AM, Apolo AB, Babjuk M, Bivalacqua TJ, et al
    Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
    J Clin Oncol. 2023 Oct 4:JCO2300307. doi: 10.1200/JCO.23.00307.
    >> Share

    September 2023
  13. SIEFKER-RADTKE AO, Cauley D, Alhalabi O
    Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:4084-4086.
    >> Share

    August 2023
  14. VON DER MAASE H, Hansen SW, Roberts JT, Dogliotti L, et al
    Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
    J Clin Oncol. 2023;41:3881-3890.
    >> Share

  15. SMALL EJ
    Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
    J Clin Oncol. 2023;41:3879-3880.
    >> Share

  16. STEIN JP, Lieskovsky G, Cote R, Groshen S, et al
    Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients.
    J Clin Oncol. 2023;41:3772-3781.
    >> Share


  17. JCO Flashback: Long-Term Outcomes of Radical Cystectomy in Patients With Invasive Bladder Cancer (2001).
    J Clin Oncol. 2023;41:3771.
    >> Share

  18. BOSL GJ
    Flashback Foreword: Radical Cystectomy in the Treatment of Bladder Cancer.
    J Clin Oncol. 2023;41:3769-3770.
    >> Share

    July 2023
  19. SWINTON M, Mariam NBG, Tan JL, Murphy K, et al
    Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Jul 21:JCO2300725. doi: 10.1200/JCO.23.00725.
    >> Share

  20. POWLES T, Park SH, Caserta C, Valderrama BP, et al
    Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After >/=2 Years of Follow-Up.
    J Clin Oncol. 2023;41:3486-3492.
    >> Share

    June 2023
  21. SARFATY M, Golkaram M, Funt SA, Al-Ahmadie H, et al
    Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
    J Clin Oncol. 2023;41:3225-3235.
    >> Share

    March 2023
  22. COLEMAN JA, Yip W, Wong NC, Sjoberg DD, et al
    Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
    J Clin Oncol. 2023;41:1618-1625.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016